"Poliagonist" names no number. It takes poli-, the Romanian form of poly-, and says only many: one engineered amino acid chain that speaks to more than one receptor, without deciding in advance how many. That is deliberately the general case — the numbered rungs each have their own page, and this one holds the question they all descend from: why engage several receptors with a single chain at all, and what does the word "agonist" have to carry for that to mean anything?
At Panacea Bio Chem, Bogdan Dicoias runs an amino acid chain (AAC) design practice: sequences are engineered residue by residue, folded, and profiled against receptor panels. The Poliagonist series is the count-free end of that practice: the programme fixes the method — one chain, tuned position by position, addressing a chosen receptor set — and leaves the size of that set as an outcome of the design rather than a headline decided before the work. Where a specific count is the subject, it belongs on the page that owns that count, not here.
Honesty boundary: this is a design-stage research programme. We publish the concept, the public science it stands on, and the design philosophy — we do not claim a finished molecule, binding data, or any clinical result here. The specific receptor constellation and sequence work remain Panacea intellectual property while the programme matures.
Illustrative programme disclosure · no results are claimed on this page
"The field counted one, then two, then three — and each step looked excessive until it worked. We do not assume the counting stops at three. An amino acid chain has enough addressable surface to speak to more than one receptor; the craft is choosing which voices belong in one chord, and tuning every residue so the chord holds."
Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd
Receptors are the cell's antennas — proteins that read chemical signals and convert them into action. The vocabulary of modern pharmacology begins with two words.
An agonist binds a receptor and activates it, standing in for the body's own signal. Insulin, adrenaline and GLP-1 all act through receptors; the medicines built on them are agonists.
An antagonist occupies the same docking site but flips nothing: it physically prevents the natural signal from getting through. Beta-blockers and antihistamines are everyday examples.
For a century the art of drug design was narrowing: one molecule, one receptor, minimal cross-talk. Fewer targets meant fewer surprises — and, often, less reach than a disease demands.
Metabolic and neurological diseases are network problems. Morphy and Rankovic formalised the counter-strategy in 2005: design one ligand to engage several receptors on purpose — a "designed multiple ligand" (J. Med. Chem. 2005).
Before anyone could design a molecule for several receptors, the receptor itself had to be argued into existence — and then split into kinds. Four moments carry that argument, and they are why a page that claims no number can still say something exact.
Working on nicotine and curare in striated muscle, John Newport Langley argued that the drug acts on a receptive substance belonging to the cell, not on the nerve ending and not on the contractile machinery. It is the first clean statement of the thing every agonist is an agonist of (Langley, J. Physiol. 1905).
Raymond Ahlquist ranked six sympathomimetic amines by potency, tissue by tissue, and found the order itself changed with the tissue — which a single receptor cannot do. He concluded there were two adrenotropic receptors, alpha and beta (Ahlquist, Am. J. Physiol. 1948). Receptor subtypes begin here, and with them the idea that "which receptors" is a choice a designer makes.
Robert Lefkowitz and Brian Kobilka shared the Nobel Prize in Chemistry for the studies of G-protein-coupled receptors that turned Ahlquist's inference into isolated, sequenced and finally crystallised proteins (Nobel Prize in Chemistry 2012). A designer can aim at a structure; nobody can aim at an inference.
Richard Morphy and Zoran Rankovic gave the counter-strategy its name: the designed multiple ligand, one molecule built to engage several targets deliberately rather than by accident of promiscuity (Morphy & Rankovic, J. Med. Chem. 2005). The rest of this page is a consequence of that sentence.
Two words still do the work. An agonist binds a receptor and switches it on, standing in for the body's own signal; an antagonist occupies the same site and lets nothing through. For a century the craft was narrowing — one molecule, one receptor, as little cross-talk as could be managed. A designed multiple ligand is the deliberate opposite, and it is only coherent because 1905 and 1948 happened first.
The rest of the Panacea agonist lane counts. This page does not, and the difference is the point: a count is a commitment, and a commitment made before the design work is a claim nobody has earned yet.
Poli- is the Romanian spelling of the Greek poly-, "many". It is a quantity word with no quantity in it — which is exactly the commitment this programme is willing to make in public: more than one receptor, addressed on purpose, by one chain. How many is a result, not a promise.
Two receptors: tirzepatide, a GIP/GLP-1 peptide, outperformed semaglutide on glucose control in type 2 diabetes (Frías et al., N. Engl. J. Med. 2021) and reached roughly 20.9% mean body-weight reduction over 72 weeks (Jastreboff et al., N. Engl. J. Med. 2022). Three: retatrutide added the glucagon receptor, about 24.2% at 48 weeks in phase 2 (Jastreboff et al., N. Engl. J. Med. 2023). The two tirzepatide readouts are SURPASS-2 and SURMOUNT-1, and the drug is approved by the FDA as Mounjaro (2022) and Zepbound (2023). Retatrutide has since reached phase 3: TRIUMPH-4 (Lilly, December 2025) reported about 28.7% mean weight loss at 68 weeks, the first successful phase 3 for a triple agonist (Lilly announcement).
The incretin pair is not the only dual in the clinic, and reading only the Western trial record makes it look as though it were. Mazdutide, a GLP-1/glucagon dual peptide developed by Innovent Biologics with Eli Lilly, was tested once-weekly in Chinese adults with obesity or overweight (Ji et al., N. Engl. J. Med. 2025), and its 9-mg dose was reported in the GLORY-2 randomised clinical trial (Gao et al., JAMA 2026). Different receptor pair, different trial population, same design idea.
Matthias Tschöp and Richard DiMarchi call it unimolecular polypharmacy: one molecule carries a fixed ratio of activities, so the balance between receptors is engineered once and travels with the dose instead of being re-created by two separate pharmacokinetic curves (Tschöp et al., Cell Metab. 2016; the first unimolecular dual incretins, Finan et al., Sci. Transl. Med. 2013).
This lane is split deliberately so that no two pages argue the same point. If you arrived looking for a number, it is answered elsewhere:
Nothing on this page is a result of ours. The medicines named above belong to the companies that ran the trials, and every trial is cited so a reader can check it without going through us.
Where the receptor idea came from, what "designed multiple ligand" means, the published trial record of the duals and the triple, and the reason Panacea's count-free programme is stated as a direction rather than a number.
Receptor sets, sequences, folding routes, assay output, timelines. None of it is withheld as a tease — a programme of this kind earns its claims in the literature, and until it has, a webpage is the wrong place for them.
"Poli-" is the Romanian form of the Greek poly-, meaning many. The name says that one engineered peptide engages more than one receptor on purpose — and deliberately says nothing about how many.
No, and that is the distinction from the numbered pages in this lane. The programme commits to the method — one chain, one engineered balance of activities — and treats the size of the receptor set as an outcome of the design work rather than a figure announced ahead of it.
Two and three are what the published record carries: tirzepatide at GIP and GLP-1, mazdutide at GLP-1 and glucagon, and retatrutide at GIP, GLP-1 and glucagon in phase 2. Each is cited above with its trial. Nothing beyond three has a comparable public record, and this page does not supply one.
It holds the general case and the history. The counts live on octogonist.com (eight), decagonist.com (ten) and multiagonist.com (the ladder, rung by rung); the design theory lives on multigonist.com. The credited timeline behind all of them is on The Research, and further questions on the Questions page.
A molecule that binds a receptor and switches it on, mimicking the body's own signal. An antagonist binds the same site and blocks the signal instead.
One molecule engineered to activate several receptors at once — a designed multiple ligand. Tirzepatide (two) and retatrutide (three) are the clinical landmarks.
No approved medicine engages many receptors by design; the clinical frontier today is triple agonism. Panacea's Poliagonist series is a design-stage programme, presented as such.
Morphy and Rankovic formalised designed multiple ligands in 2005; Tschöp and DiMarchi advanced unimolecular polypharmacology; Eli Lilly brought tirzepatide and retatrutide to the clinic. The credited timeline is on The Research.
Recent developments in the field — refreshed 2026-07-26 by Panacea Bio Chem.
The Panacea Technology Universe
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.lyoprester.com ↗
P-EARLs™Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.p-earls.com ↗
Peptourbillon™The layered peptide formulation architecture — single- or multi-layer, never a blend.peptourbillon.com ↗
RF Tunnel™The RF-formed central channel through the cake.rftunnel.com ↗
TgShift™Raises the cake’s glass-transition temperature with RF — instead of chilling below it.tgshift.com ↗
Cryolapse™Cryogenic pressure collapse under S3Pulse™ control — vapour redistributed through the whole cake, not its surface, impeding crust formation.cryolapse.com ↗
LyoLevit™The cake levitates and spins in high orbit — driven by ultrasound and RF.lyolevit.com ↗
Lyochrysalis™The integrated chamber housing the whole drying stack.lyochrysalis.com ↗
S3Pulse™The control brain for every piece of Panacea hardware.s3pulse.com ↗
Liquiprester™The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.liquiprester.com ↗
Syntheseract™Continuous-flow peptide synthesis in a special, very fast and economical way.syntheseract.com ↗
CFSPPS™Continuous-flow solid-phase peptide synthesis, written as its own category.cfspps.com ↗
OxyDeplete™Degassing plus no-headspace doctrine — the oxygen-starved seal.oxydeplete.com ↗
ArgonLock™The final inert-atmosphere lock under argon.argonlock.com ↗
RedoxVault™Separation, not merely suppression — redox isolation in lipid micro-reservoirs.redoxvault.com ↗
PleniDose™The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.plenidose.com ↗
IncreSure™The dose-metrology layer — verified API per pen increment.incresure.com ↗
ElimiVoid™Front-void elimination without touching the metered dose.elimivoid.com ↗
Cryoviscous™The characterised cold, high-viscosity, low-mobility conditioning state.cryoviscous.com ↗
Vana Machine™Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
EZnject™The disposable auto-injector pen built around the Lyoprester.panaceaeznject.com ↗
Dicoias ΨThe computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.dcppsi.com ↗
SealoPrester™Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.sealoprester.com ↗
Peptidic LiquidThe peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.peptidicliquid.com ↗
DiastolVAC™Biomimetic diastolic vacuum control — the pneumatic circulatory system of the machine: pumps, valves and sensors as one ensemble.diastolvac.com ↗
KineticON™Motion Integrity Architecture — the motion-control layer that lets the machine know what happened on every axis move.kineticon.org ↗No publication indexed in PubMed in the last 30 days for "poliagonist" OR "multi-receptor agonist" — the most recent in the field, refreshed weekly.